OTCQX:MRVFF - Post by User
Post by
blackascanbeon Feb 22, 2012 9:21am
496 Views
Post# 19565679
prested I agree
prested I agree If Nuvo isn't cash flow positive within 12 to 18 months I doubt there will be any further equity issues, certainly at prices anywhere near the current level. We could easily see a sale of the company for about $1.00 per share. With 3 FDA approved drugs, a technology pipeline, WF10 successful phase 2 for allergic rhinitis, not to mention other immune system modulating applications. A buck would be a deal for the buyer!!